MSD
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MSD
Homegrown China Oral Antiviral Shows Early Promise
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
Scotland Okays Funding For Keytruda and Opdivo For Esophageal Cancer, Among Other Drugs
Immunotherapies for esophageal cancer from BMS and MSD are among the medicines that Scotland’s health technology appraisal body has recommended for use on the National Health system.
How Ex-Janssen India Chief Is Steering Bharat Serums’ Ambitions In Women’s Health
Sanjiv Navangul, managing director and CEO, Bharat Serums and Vaccines, in a wide-ranging interview with Scrip, outlines the firm’s game plan to establish itself as a “force to reckon with” in women’s health - it goes beyond drugs and encompasses devices and potentially digital therapeutics as well. The former Janssen India chief also weighs in on the worrying industry-wide input cost escalation scenario and supply chain turbulence.
NICE Overturns Bavencio Rejection After Merck/Pfizer Win Appeal On English Funding
As well as now backing the reimbursement of Bavencio for urothelial cancer, the health technology assessment institute has recommended Koselugo, for neurofibromatosis type 1, and Evenity, the osteoporosis drug that will now target over 20,000 people in England and Wales. On the other hand, Piqray has for now been turned down for advanced breast cancer.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Merck Sharpe & Dome